Bevifimod

Cat. No.:	HY-P99477
CAS No.:	2223113-32-2
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Bevifimod (PRTX-100) is a highly purified form of Staphylococcal protein A (SpA). Bevifimod can be used for idiopathic thrombocytopenic purpura (ITP) research[1][2].
In Vitro	Bevifimod (PRTX-100; 250, 25, and 2.5 ng/mL; 48 hours) inhibits the phagocytosis of W632 opsonized platelets by human monocytes in peripheral blood mononuclear cells (PBMCs)[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Bevifimod□PRTX-100□2.5-250 μg/kg□i.v.□□□□□□□□□□ 4 □□□ 1-2 □□□□□□□□□□□□□□□□□□□□□□□□□□□□[2]□ MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SCID mice bearing immune thrombocytopenia (ITP)[2]
Dosage:	2.5 μg/kg, 25 μg/kg, 250 μg/kg
Administration:	i.v.; once every two weeks; for 4 weeks
Result:	Raised platelet counts in a well-established murine model of ITP.

REFERENCES

[1]. ChrisYatkoBS, et al. PRTX-100 Inhibits Platelet Phagocytosis In Vitro. Blood (2006) 108 (11): 1081.

[2]. John W. Semple, et al. Successful Treatment of Thrombocytopenia with Staphylococcal Protein A (PRTX-100) in a Murine Model of Immune Thrombocytopenia (ITP). Blood (2015) 126 (23): 1045.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA